Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Marc Binder"'
6
Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial
Autor: Martin Bornhäuser, Uwe Platzbecker, Gerhard Ehninger, Jörgen Radke, Johannes Schetelig, Marc Binder, Jan Stoehlmacher, Eray Goekkurt, Christian Thiede, Malte von Bonin, Alexander Kiani
Publikováno v: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(1)
A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4a03a2c7429e17d755b756856b00b6e
https://pubmed.ncbi.nlm.nih.gov/19135948
Zobrazit plný text záznamu
7
Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation
Autor: Christoph Schmid, Claudia Rutt, Gerhard Ehninger, Marc Binder, Uwe Platzbecker, Martin Bornhäuser
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative approach for a variety of hematologic malignant and non-malignant disorders. With the rising number of stem cell transplantations from unrelated donors over the last years,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f818bb689622c0cf0e3c31f1bac7b412
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/99422
Zobrazit plný text záznamu
8
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus
Autor: Uwe Platzbecker, Martin Bornhäuser, Brigitte Mohr, Johannes Schetelig, Marc Binder, M von Bonin, G. Ehninger
Publikováno v: Leukemia. 21(11)
Myelodysplastic syndromes (MDSs) comprise a heterogeneous group of disorders. Recently, the WHO (World Health Organization) defined several new categories also separating chronic myelomonocytic leukemia (CMML)-1 from CMML-2 according to blast percent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d26b617138d4f5d611fef1a38ad2cf9
https://pubmed.ncbi.nlm.nih.gov/17581611
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje